Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia
Authors
Keywords
-
Journal
Molecular Cancer
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-06
DOI
10.1186/s12943-023-01837-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination
- (2023) Hyunbin D. Huh et al. Molecular Cancer
- Acute myeloid leukemia: current progress and future directions
- (2021) Hagop Kantarjian et al. Blood Cancer Journal
- Towards precision medicine for AML
- (2021) Hartmut Döhner et al. Nature Reviews Clinical Oncology
- Hot Spot Analysis of YAP-TEAD Protein-Protein Interaction Using the Fragment Molecular Orbital Method and Its Application for Inhibitor Discovery
- (2021) Jongwan Kim et al. Cancers
- Response and Resistance to BCR-ABL1-Targeted Therapies
- (2020) Theodore P. Braun et al. CANCER CELL
- Targeting FLT3 mutations in AML: review of current knowledge and evidence
- (2019) Naval Daver et al. LEUKEMIA
- Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival
- (2019) Brett M. Noel et al. JOURNAL OF PROTEOME RESEARCH
- FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications
- (2019) Julhash U. Kazi et al. PHYSIOLOGICAL REVIEWS
- Regulation of TEAD Transcription Factors in Cancer Biology
- (2019) Hyunbin D. Huh et al. Cells
- YAP and TAZ are dispensable for physiological and malignant haematopoiesis
- (2018) Elisa Donato et al. LEUKEMIA
- Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
- (2018) Simona Soverini et al. Molecular Cancer
- CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
- (2017) Niklas Landberg et al. HAEMATOLOGICA
- RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia
- (2017) Ayuna Hattori et al. LEUKEMIA RESEARCH
- CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
- (2017) Niklas Landberg et al. HAEMATOLOGICA
- Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche
- (2016) Haobin Ye et al. Cell Stem Cell
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway
- (2015) Jung-Soon Mo et al. NATURE CELL BIOLOGY
- Allogeneic transplantation for CML in the TKI era: striking the right balance
- (2015) Andrew J. Innes et al. Nature Reviews Clinical Oncology
- Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers
- (2014) Francesca Cottini et al. NATURE MEDICINE
- Biomarkers for determining the prognosis in chronic myelogenous leukemia
- (2013) Kendra Sweet et al. Journal of Hematology & Oncology
- How I treat CML blast crisis
- (2012) R. Hehlmann BLOOD
- Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis
- (2012) B. Zhao et al. GENES & DEVELOPMENT
- Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies
- (2011) J. M. Gozgit et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More